- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04384718
Assessing the Generalizability of the Tachidino Protocol to Different Clinical Contexts
Assessing the Generalizability of the Tachidino Protocol for Intervention on Reading and Spelling Disorders to Different Clinical Contexts
Study Overview
Status
Conditions
Detailed Description
Specifically, the intervention system based on the web platform "Tachidino" and routinely used for the rehabilitation of reading and spelling disorders at Medea, Lombardy region, would be extended to Marche (precisely, the clinical service connected to Urbino University, located in Pesaro, a coastal town in Central Italy), a different geographical region with different population characteristics. Precisely, the Lombardy region is a highly industrialized region with the highest digitalization rate in Italy, whereas Marche is a more agriculture-oriented region, with lower population density and less widespread use of digital technologies. The main aim of the study is, then, to ascertain whether the effectiveness levels found for the treatment protocol in the original context generalize to a different context and population.
The system for the empowerment of reading and spelling skills ("Tachidino" software) is based on two principles of proven effectiveness:
- The selective stimulation of a cerebral hemisphere and specific reading strategies.
- The training of selective visuospatial attention, as well as the perception of rapid movement and the control of visual crowding effects.
Clinical and assessment procedures
In current clinical practice at IRCCS Medea, intervention in "e-health" mode is divided into one or more rehabilitation modules through the use of the Tachidino platform, with systematic monitoring and motivational reinforcement by professionals with experience in e-health approaches. In order to be included in the training, the child must have already obtained a diagnosis of dyslexia, according to the current diagnostic standards.
The structure of the intervention modules is as follows:
- 1 initial meeting to get to know the child, pre-test assessment - reading and writing tests of words, non-words and sentences, metaphonological tests and text reading tests (reading accuracy and speed) in order to define dyslexia subtypes; intervention planning - demonstration of Tachidino use and programming of first activities
- telephone support to monitor and motivate correct use of the software, during active intervention
- 1 final assessment meeting (with repetition of the tests used at pre-test and compilation of questionnaires).
In addition to the main goal and the above-described procedure, the study will investigate the effects of treatment with additional tests providing parallel versions and lists of stimuli, so as to exclude any possible repetition effect and thus to better highlight "pure" intervention effects.
Participants' characteristics: Children aged between 7 and 16 years with a diagnosis of Specific Reading Disorder, Mixed Disorder of Scholastic Skills or Developmental Dyslexia, pertaining to International Classification of Diseases (ICD-10) codes F81, F81.0, F81.3, referred to one of the two participating centres because of school learning problems.
Total number of subjects: 32 (16 per centre). An additional group of 16 children with Dyslexia and/or Dysgraphia on a waiting list will also be tested and retested after 4 weeks, providing a further control for the effects of intervention.
The number of participants has been determined with a power analysis based on data on the effects of treatment observed in the group already treated with Tachidino at IRCCS Medea. The number of 32 participants turned out to be sufficient to provide a power of 0.8 with alpha set at .005.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Pesaro, Italy
- ASUR Marche, Centre for Clinical Child Neuropsychology
-
Urbino, Italy
- University of Urbino
-
-
LC
-
Bosisio Parini, LC, Italy, 23842
- Scientific Institute IRCCS E. Medea
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- A formal diagnosis of Developmental Dyslexia, Specific Reading Disorders, or Mixed Scholastic Learning Disorders
- Age between 7 and 16
- Attending at least the third class of primary school
- Monolingual speakers of Italian or bilingual speakers with perfect mastery of the Italian language (equivalent to monolinguals)
- Intelligence Quotient (IQ) >= 80
- At least one z-score below -2 Standard Deviations from age mean in at least one of the following tests: text reading, word reading, nonword reading ("DDE-2" battery, "MT" tests)
- Not having received any specific rehabilitation treatment for dyslexia before
Exclusion Criteria:
- Intellectual disability
- Neurological disorders
- Sensory deficits that are not /cannot be corrected-to-normal by lenses or hearing aids.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Medea Group
Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
|
|
Asur Group
Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
|
|
Waiting list Group
Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change from pre-test to post-test in reading ability
Time Frame: 4 weeks
|
Difference in treatment-related changes (post-test minus pre-test) observed in reading measures (speed and accuracy in word, nonword and text reading standardized tests: Memory Training (MT) group reading test and "Developmental Dyslexia and Dysgraphia" (DDE-2); average of the scores expressed as z-scores with respect to age norms)
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change from pre-test to post-test in metaphonological ability
Time Frame: 4 weeks
|
Difference in treatment-related changes (post-test minus pre-test) observed in metaphonological tests (phonemic analysis and phoneme blending) - average of the number of errors in the two tests
|
4 weeks
|
|
change from pre-test to post-test in short-term-memory
Time Frame: 4 weeks
|
Difference in treatment-related changes (post-test minus pre-test) observed in memory tests (direct and indirect span) - average of the number of correct responses in the two tests
|
4 weeks
|
|
change from pre-test to post-test in executive functions
Time Frame: 4 weeks
|
Difference in treatment-related changes (post-test minus pre-test) observed in executive functions tests (go-no-go paradigm) - average of the number of correct responses in the two tests
|
4 weeks
|
|
difference in change between treated and untreated children
Time Frame: 4 weeks
|
Difference found in pre-post test changes (post-test minus pre-test) observed in reading tests (reading speed and accuracy measured with "MT tests" and "DDE-2") - expressed as z-scores according to age, between the two groups treated with Tachidino remotely delivered intervention and the waiting list group
|
4 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-20 oss (to be confirmed)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Developmental Dyslexia
-
Georgia State UniversityMedical University of South Carolina; National Institutes of Health (NIH)CompletedDevelopmental Reading Disorder | Dyslexia, DevelopmentalUnited States
-
IRCCS Eugenio MedeaCompletedDevelopmental Dyslexia | Developmental Spelling DisorderItaly
-
University Hospital, ToulouseCompletedDevelopmental Dyslexia | Developmental Coordination DisorderFrance
-
Ahmet EmirCompletedIntellectual Disability | Developmental Dyslexia | Developmental DisabilityTurkey
-
Georgia State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedDyslexia | Dyslexia, Developmental | Learning; Developmental Disorder, ReadingUnited States
-
Catholic University of the Sacred HeartFondazione Policlinico Universitario Agostino Gemelli IRCCS; Fondazione I.R...Enrolling by invitationDevelopmental DyslexiaItaly
-
University of ZurichUnknown
-
CNGE IRMG AssociationScalab CNRS 9193UnknownSpecific Learning Disorder | Developmental Coordination Disorder | Specific Developmental Disorders of Speech and Language | Dyslexia, Developmental | DyspraxiaFrance
-
IRCCS Eugenio MedeaRecruitingDevelopmental Dyslexia | Developmental Language DisorderItaly
-
Bambino Gesù Hospital and Research InstituteRecruitingDevelopmental DyslexiaItaly